Home › Companies › TARSUS PHARMACEUTICALS INC. › 2023-2024
At TARSUS PHARMACEUTICALS INC.'s shareholder meeting held June 13, 2024, in the 2023-2024 proxy season, 64 asset managers reported how they voted in their SEC Form N-PX filings, covering 528 separate fund positions. Their filings are grouped here into 3 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. TARSUS PHARMACEUTICALS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Ratification of the appointment of Ernst & Young LLP as our independent registered public… — the reporting funds cast 100% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and TARSUS PHARMACEUTICALS INC.’s Form 8-K, filed June 18, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 13, 2024: 3 items on TARSUS PHARMACEUTICALS INC.’s Form 8-K, filed June 18, 2024: 2 elected · 1 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore TARSUS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are TARSUS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Bhaskar Chaudhuri, Ph.D. | 21,766,101 | -- | -- | 2,941,857 | 7,270,980 | 88% | Elected | — |
| Elect Director: William J. Link, Ph.D. | 20,817,032 | -- | -- | 3,890,926 | 7,270,980 | 84% | Elected | — |
| The number of votes cast for and against and the number of abstentions for this proposal were as follows (there were no broker non-votes for this proposal) | 31,896,705 | 24,949 | 57,284 | -- | -- | 99.9% | Approved | — |
Source: TARSUS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 18, 2024 — read the filing on EDGAR.
Each item below shows how the 64 asset managers that disclosed a TARSUS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of TARSUS PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: To re-elect the following two nominees as Class I directors, to serve until the 2027 annual meeting of stockholders or until their respective successor have been elected or appointed: Bhaskar Chaudhuri
TARSUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bhaskar Chaudhuri, Ph.D.”): 21,766,101 for, 2,941,857 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class I directors for a term that will continue until the 2027 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 5,192,083 for, 876,098 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,788,193 | 0 | 0 | 0 | For |
| BlackRock | 677,822 | 0 | 0 | 0 | For |
| Prudential/PGIM | 635,824 | 0 | 0 | 0 | For |
| Artisan | 392,843 | 0 | 0 | 0 | For |
| TIAA | 312,993 | 0 | 0 | 0 | For |
| Invesco | 312,761 | 0 | 0 | 0 | For |
| T. Rowe Price | 279,282 | 0 | 0 | 0 | For |
| Charles Schwab | 222,192 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 150,000 | Withhold |
| Allspring | 0 | 0 | 0 | 124,366 | Withhold |
| Equitable | 50,322 | 0 | 0 | 45,456 | Mixed |
| SEI | 94,280 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 0 | 0 | 0 | 85,038 | Withhold |
| Baird | 0 | 0 | 0 | 77,979 | Withhold |
| Calamos | 72,479 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 72,032 | Withhold |
| Lord Abbett | 0 | 0 | 0 | 56,846 | Withhold |
| Dimensional | 0 | 0 | 0 | 54,718 | Withhold |
| Columbia Threadneedle | 53,643 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 47,248 | 0 | 0 | 0 | For |
| State Street | 44,106 | 0 | 0 | 291 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 34,272 | Withhold |
| Nushares ETF Trust | 27,436 | 0 | 0 | 0 | For |
| Fidelity | 26,339 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 26,243 | Withhold |
Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Description as filed by funds: To re-elect the following two nominees as Class I directors, to serve until the 2027 annual meeting of stockholders or until their respective successor have been elected or appointed: William J. Link
TARSUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: William J. Link, Ph.D.”): 20,817,032 for, 3,890,926 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class I directors for a term that will continue until the 2027 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 4,869,768 for, 1,198,413 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,788,193 | 0 | 0 | 0 | For |
| BlackRock | 677,822 | 0 | 0 | 0 | For |
| Prudential/PGIM | 635,824 | 0 | 0 | 0 | For |
| Artisan | 392,843 | 0 | 0 | 0 | For |
| TIAA | 312,993 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 312,761 | Withhold |
| T. Rowe Price | 279,282 | 0 | 0 | 0 | For |
| Charles Schwab | 222,192 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 150,000 | Withhold |
| Allspring | 0 | 0 | 0 | 124,366 | Withhold |
| Equitable | 50,322 | 0 | 0 | 45,456 | Mixed |
| SEI | 94,280 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 0 | 0 | 0 | 85,038 | Withhold |
| Baird | 0 | 0 | 0 | 77,979 | Withhold |
| Calamos | 72,479 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 72,032 | Withhold |
| Lord Abbett | 0 | 0 | 0 | 56,846 | Withhold |
| Dimensional | 0 | 0 | 0 | 54,718 | Withhold |
| Columbia Threadneedle | 53,643 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 47,248 | 0 | 0 | 0 | For |
| State Street | 44,106 | 0 | 0 | 291 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 34,272 | Withhold |
| Nushares ETF Trust | 27,436 | 0 | 0 | 0 | For |
| Fidelity | 26,339 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 26,243 | Withhold |
Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
100% of fund votes cast · no official result
Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
The 64 asset managers below reported 6,068,181 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,788,193 | 0 | 0 | 0 | For |
| BlackRock | 677,822 | 0 | 0 | 0 | For |
| Prudential/PGIM | 635,824 | 0 | 0 | 0 | For |
| Artisan | 392,843 | 0 | 0 | 0 | For |
| TIAA | 312,993 | 0 | 0 | 0 | For |
| Invesco | 312,761 | 0 | 0 | 0 | For |
| T. Rowe Price | 279,282 | 0 | 0 | 0 | For |
| Charles Schwab | 222,192 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 150,000 | 0 | 0 | 0 | For |
| Allspring | 124,366 | 0 | 0 | 0 | For |
| Equitable | 95,778 | 0 | 0 | 0 | For |
| SEI | 94,280 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 85,038 | 0 | 0 | 0 | For |
| Baird | 77,979 | 0 | 0 | 0 | For |
| Calamos | 72,479 | 0 | 0 | 0 | For |
| Aberdeen | 72,032 | 0 | 0 | 0 | For |
| Lord Abbett | 56,846 | 0 | 0 | 0 | For |
| Dimensional | 54,718 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 53,643 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 47,248 | 0 | 0 | 0 | For |
| State Street | 44,397 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 34,272 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 27,436 | 0 | 0 | 0 | For |
| Fidelity | 26,339 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 26,243 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 37,781,693 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.73% |
| 2 | BlackRock | 1.79% |
| 3 | Prudential/PGIM | 1.68% |
| 4 | Artisan | 1.04% |
| 5 | TIAA | 0.83% |
| 6 | Invesco | 0.83% |
| 7 | T. Rowe Price | 0.74% |
| 8 | Charles Schwab | 0.59% |
| 9 | Delaware/Macquarie | 0.40% |
| 10 | Allspring | 0.33% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Jackson Creek Investment Advisors LLC | <0.01% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 10.00% | 13F |
| RTW Investments L.P. | 8.34% | DEF14A |
| TANG CAPITAL MANAGEMENT, LLC | 6.50% | 13G |
| Paradigm BioCapital Advisors LP | 6.46% | 13G |
| Vanguard Group | 6.01% | 13F |
| Cormorant Asset Management, LP | 5.88% | DEF14A |
| Tang Capital Partners, LP | 5.84% | DEF14A |
| Horowitz Limited Partnership VIII | 5.33% | DEF14A |
| Bobak Azamian | 5.08% | DEF14A |
| Morgan Stanley | 5.06% | 13F |
Percentages above are of 37,781,693 shares outstanding, as reported by TARSUS PHARMACEUTICALS INC. on its Form 10-Q dated May 2, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from TARSUS PHARMACEUTICALS INC.’s 10-Q dated May 2, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
TARSUS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
proxyvotesnow.com, “TARSUS PHARMACEUTICALS (TARS) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/tarsus-pharmaceuticals-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.